Clinical trials: Pancreatic Cancer Metastatic
Metastatic Pancreatic Cancer
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have…
- Trial name
- NAPOLI-1 (NCT01494506)
- Testing
- MM-398, 5 Fluorouracil, Leucovorin
- Where
- 79 sites in United States, Argentina and 13 more
- Volunteers
- 417 people
- Sponsor
- Merrimack Pharmaceuticals
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of…
- Conditions
- Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
- Trial name
- CanPan-C (NCT06605430)
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- HealthPartners Institute
Pancreas Cancer
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.
- Trial name
- CHECKPOINT (NCT05435053)
- Testing
- Nivolumab, Irreversible electroporation (IRE)
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Ismail Gögenur
Advanced Solid Tumors
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable)…
- Trial name
- NCT03565445
- Testing
- ASP1948, nivolumab, pembrolizumab
- Where
- 42 sites in United States, Canada and 7 more
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC)
To confirm the safety of combining oral fecal microbiota transplantation (FMT) with gemcitabine and nab-paclitaxel chemotherapy as first line treatment in patients with unresectable or metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CHASe-PDAC (NCT06393400)
- Testing
- Fecal Microbiota Transplantation, PEG3350, Gemcitabine
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- John Lenehan
Pancreatic Cancer
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying.
- Trial name
- NCT00409292
- Testing
- RAD001
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00112528
- Testing
- bevacizumab, gemcitabine hydrochloride, oxaliplatin
- Where
- 201 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
- Trial name
- NCT00322712
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of New Mexico
Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic…
- Trial name
- PROBE (NCT07825753)
- Testing
- Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Fudan University
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Pancreatic Neuroendocrine Tumor
In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
The purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic Pancreatic…
- Trial name
- NCT06246630
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies the side effects and how well irinotecan hydrochloride, oxaliplatin and cetuximab work in treating patients with unresectable or metastatic pancreatic cancer.
- Trial name
- NCT00871169
- Testing
- Irinotecan, oxaliplatin, and cetuximab
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- New Mexico Cancer Research Alliance
Malignant Tumor of Pancreas Metastatic to Liver
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
This study is a randomized open-label phase 2b study of the efficacy and safety of regional infusion therapy with Anti-CEA CAR-T cells using the hepatic immunotherapy for metastases (HITM) method and the Trisalus pressure…
- Trial name
- NCT04037241
- Testing
- Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA
- Sponsor
- Sorrento Therapeutics, Inc.
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
- Trial name
- NCT06361888
- Testing
- Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
- Where
- 52 sites in China
- Volunteers
- 502 people
- Sponsor
- Hutchmed
Pancreatic Neoplasms, Pancreatic Cancer
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Adenocarcinoma
- Trial name
- NCT01161186
- Testing
- nab-paclitaxel, gemcitabine, capecitabine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Metastatic Pancreatic Adenocarcinoma
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic…
- Trial name
- REVOLUTION (NCT04787991)
- Testing
- Nivolumab (Cohort A), Ipilimumab (Cohort A, B and C), Hydroxychloroquine (HCQ) (Cohort B)
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cancer Insight, LLC
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602082
- Testing
- capecitabine, cisplatin, streptozocin
- Where
- 17 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust